Free Trial

Gilead Sciences, Inc. $GILD Shares Acquired by Bessemer Group Inc.

Gilead Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Bessemer Group increased its Gilead stake by 17.7% in the third quarter, adding 254,994 shares to hold about 1.70 million shares worth $253.2 million.
  • Gilead beat quarterly estimates, reporting EPS of $2.55 versus $2.19 expected and revenue of $8.30 billion, up 6.8% year over year.
  • Analysts’ consensus rating was “Moderate Buy,” with a $171.07 average price target; meanwhile, company insiders sold 211,709 shares over the prior 90 days.
  • MarketBeat previews the top five stocks to own by December 1st.

Bessemer Group Inc. increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,699,016 shares of the biopharmaceutical company's stock after buying an additional 254,994 shares during the quarter. Bessemer Group Inc. owned 0.14% of Gilead Sciences worth $253,238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. FDx Advisors Inc. bought a new stake in shares of Gilead Sciences in the third quarter valued at $201,000. Optas LLC raised its stake in Gilead Sciences by 14.1% in the 3rd quarter. Optas LLC now owns 4,341 shares of the biopharmaceutical company's stock valued at $647,000 after acquiring an additional 538 shares during the period. Phoenix Financial Ltd. raised its stake in Gilead Sciences by 5.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 25,618 shares of the biopharmaceutical company's stock valued at $3,819,000 after acquiring an additional 1,302 shares during the period. Danica Pension Livsforsikringsaktieselskab purchased a new stake in Gilead Sciences during the third quarter valued at about $863,000. Finally, Danske Bank A S lifted its holdings in Gilead Sciences by 27.1% during the third quarter. Danske Bank A S now owns 1,068,347 shares of the biopharmaceutical company's stock valued at $159,237,000 after purchasing an additional 227,947 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CEO Daniel O'Day sold 102,619 shares of the company's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the completion of the sale, the chief executive officer owned 551,683 shares of the company's stock, valued at $96,632,794.28. This represents a 15.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of the company's stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the sale, the executive vice president directly owned 5,360 shares of the company's stock, valued at $879,629.60. The trade was a 38.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 211,709 shares of company stock valued at $35,234,427 in the last 90 days. Insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GILD. Morgan Stanley increased their target price on shares of Gilead Sciences from $163.00 to $183.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Bank of America boosted their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a "buy" rating in a research report on Tuesday, October 20th. TD Cowen upped their price target on shares of Gilead Sciences from $160.00 to $175.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Scotiabank raised their price objective on shares of Gilead Sciences from $177.00 to $200.00 and gave the stock a "sector outperform" rating in a report on Friday, October 30th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and issued a $184.00 price objective on shares of Gilead Sciences in a report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus price target of $171.07.

Read Our Latest Stock Report on GILD

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $168.08 on Monday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. The firm has a market cap of $208.48 billion, a PE ratio of -53.19 and a beta of 0.35. The business has a 50 day moving average price of $155.10 and a 200-day moving average price of $141.80. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $176.58.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business's revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.47 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post -0.97 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences's payout ratio is presently -103.80%.

Key Headlines Impacting Gilead Sciences

Investors following GILD have been watching these headlines:

  • Positive Sentiment: Coverage points to momentum in Gilead’s HIV franchise: Yeztugo sales are described as surging, Biktarvy remains a market leader, and the expanding pipeline could support longer-term growth. Read More..
  • Neutral Sentiment: Gilead announced a partnership with TelevisaUnivision to promote HIV-prevention awareness at the Latin GRAMMY Awards. It may build awareness, but the announcement does not specify a direct near-term financial impact. Read More..
  • Neutral Sentiment: A broader pharmaceutical-stock article highlighted Gilead’s dividend and pipeline as defensive attributes, but offered no company-specific new financial or operating catalyst. Read More..

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines